Terms ending in 2027
Every in-force patent on Aventis Pharma S.A.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,935,819 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors In force · High confidence | Aventis Pharma S.A. | In force | High confidence | |
| US 7,674,795 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof In force · High confidence | Aventis Pharma S.A.. | In force | High confidence | |
| US 8,058,290 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof In force · High confidence | Aventis Pharma S.A.. | In force | High confidence | |
| US 8,608,961 | Method for Affinity Chromatography of Antithrombin III In force · High confidence | Sanofi Mature IP | In force | High confidence | |
| US 8,211,676 | Cholesterol-Producing Yeast Strains and Uses Thereof In force · High confidence | Euroapi France | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Aventis Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.